Lixte Biotechnology Holdings (FRA:8640) Total Liabilities : €0.29 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lixte Biotechnology Holdings Total Liabilities?

Lixte Biotechnology Holdings's Total Liabilities for the quarter that ended in Dec. 2023 was €0.29 Mil.

Lixte Biotechnology Holdings's quarterly Total Liabilities declined from Jun. 2023 (€0.37 Mil) to Sep. 2023 (€0.29 Mil) and declined from Sep. 2023 (€0.29 Mil) to Dec. 2023 (€0.29 Mil).

Lixte Biotechnology Holdings's annual Total Liabilities increased from Dec. 2021 (€0.27 Mil) to Dec. 2022 (€0.37 Mil) but then declined from Dec. 2022 (€0.37 Mil) to Dec. 2023 (€0.29 Mil).

Lixte Biotechnology Holdings Total Liabilities Historical Data

The historical data trend for Lixte Biotechnology Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings Total Liabilities Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

0.21

0.18

0.27

0.37

0.29

Lixte Biotechnology Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															0.37	0.23	0.37	0.29	0.29

Lixte Biotechnology Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lixte Biotechnology Holdings's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.288	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.29

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	3.951	-	3.663
	=	0.29

Lixte Biotechnology Holdings's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.288	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	0.29

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	3.951	-	3.663
	=	0.29

Lixte Biotechnology Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings (FRA:8640) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (FRA:8640) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

LIXT:USA

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Lixte Biotechnology Holdings (FRA:8640) Headlines

No Headlines